AlloVir surges after FDA grants designation to its therapy

Kalaris Therapeutics

20/04/2022 12:47

** Drug developer's shares  ALVR.O  climbs 21% to $6.56
before the bell 
    ** AlloVir says U.S. Food and Drug Administration has
granted Regenerative Medicine Advanced Therapy designation to
its experimental therapy, posoleucel, for prevention of
infections and disease from six viruses  urn:newsml:reuters.com:*:nBw9sHx98a
    ** Says it has started Phase 3 multi-virus prevention trial
in March 2022 
    ** Up to Tuesday's close, stock had fallen 59% YTD 

 (Reporting by Ankur Banerjee)